Interview With Dr Kenneth Tomkovich: ICE3 Trial 3-Year Interim Results

The ICE3 trial was designed to evaluate the safety and efficacy of breast cryoablation, enabling women older than 60 years with low-risk early-stage breast cancers to benefit from a non-surgical treatment and to avoid the associated surgical risks. Dr Kenneth Tomkovich, co-principal investigator of ICE3, joined us to discuss the 3-year interim analysis, which was recently published in the Annals of Surgical Oncology.¹

To learn more about the cryoablation procedure used in this study, watch Dr. Tomkovich's video presentation, which explains why cryoablation is a promising choice for breast cancer treatment, provides an overview of the cryoablation technique with IceCure Medical's ProSense Cryoablation System, and describes proper patient selection. In addition, 2 cases are presented that illustrate common mammographic findings before and after treatment with cryoablation. 

Reference

1. Fine RE, Gilmore RC, Dietz JR, et al. Cryoablation without excision for low-risk early-stage breast cancer: 3-year interim analysis of ipsilateral breast tumor recurrence in the ICE3 trial. Ann Surg Oncol. 2021;28:5525-5534.